Statement: The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.
Primary_evidence: Adverse Events 1:   Total: 46/170 (27.06%)   Anaemia 1/170 (0.59%)   Febrile neutropenia 1/170 (0.59%)   Cardiac tamponade 1/170 (0.59%)   Myocarditis 1/170 (0.59%)   Pericardial effusion 2/170 (1.18%)   Pericarditis 1/170 (0.59%)   Colitis 1/170 (0.59%)   Constipation 1/170 (0.59%)   Diarrhoea 0/170 (0.00%)   Gastroenteritis eosinophilic 0/170 (0.00%)   Intestinal obstruction 0/170 (0.00%) Adverse Events 2:   Total: 0/1 (0.00%)   Anaemia 0/1 (0.00%)   Febrile neutropenia 0/1 (0.00%)   Cardiac tamponade 0/1 (0.00%)   Myocarditis 0/1 (0.00%)   Pericardial effusion 0/1 (0.00%)   Pericarditis 0/1 (0.00%)   Colitis 0/1 (0.00%)   Constipation 0/1 (0.00%)   Diarrhoea 0/1 (0.00%)   Gastroenteritis eosinophilic 0/1 (0.00%)   Intestinal obstruction 0/1 (0.00%)   Nausea 0/1 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 12/538 (2.23%)   Hypertension 0/538 (0.00%)   Acoustic Neuroma 1/538 (0.19%)   Diarrhea 0/538 (0.00%)   Colitis 1/538 (0.19%)   Elevated ALT or AST enzyme 7/538 (1.30%)   Diagnosis of Uterine Cancer 0/538 (0.00%)   Motorcycle accident 0/538 (0.00%)   Fall 0/538 (0.00%)   Surgery 3/538 (0.56%) Adverse Events 2:   Total: 8/537 (1.49%)   Hypertension 1/537 (0.19%)   Acoustic Neuroma 0/537 (0.00%)   Diarrhea 1/537 (0.19%)   Colitis 0/537 (0.00%)   Elevated ALT or AST enzyme 0/537 (0.00%)   Diagnosis of Uterine Cancer 2/537 (0.37%)   Motorcycle accident 1/537 (0.19%)   Fall 1/537 (0.19%)   Surgery 2/537 (0.37%)